A multicenter, open-label study of Nipent [pentostatin], Cytoxan [cyclophosphamide] and Rituxan [rituximab] in patients with previously untreated or treated chronic lymphocytic leukaemia.

Trial Profile

A multicenter, open-label study of Nipent [pentostatin], Cytoxan [cyclophosphamide] and Rituxan [rituximab] in patients with previously untreated or treated chronic lymphocytic leukaemia.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Pentostatin (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2005 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top